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IRENE’s mission is to improve the health and well-being 
of Iowans through collaboration in practice-based  
research on questions important to primary care  
physicians and their patients.  IRENE’s purpose is to  
create and foster a network of research collaboration 
between the academic medical center and primary care 
physicians throughout the state of Iowa with a particular 
focus on improving rural health. 
Our 
MISSION 
and 
PURPOSE 
AHRQ Contract Award Received to Study 
Community-Acquired MRSA 
A  new project entitled, “Management by  Primary Care  Clinicians of Patients 
Suspected of Having Commu-
nity-Acquired, Methicillin-
Resistant Staphylococcus 
Aureus (CA-MRSA) Infections,” 
has been funded by the Agency 
for Healthcare Quality and  
Research.  Principal investiga-
tors, Jeanette Daly, RN, PhD 
and Barcey Levy, PhD, MD 
have received the funding for 
two years to conduct the study 
in nine IRENE offices.  The  
purposes of the study are two-
fold: 1)  identify and evaluate 
best methods and procedures 
for primary care practices to  
follow in managing patients  
suspected of having community 
acquired methicillin-resistant 
staphylococcus aureus  
infections, and 2) disseminate 
widely those strategies found to 
be effective, efficient and  
sustainable. 
 CA-MRSA can cause illness 
in persons outside of hospitals 
and healthcare facilities.  MRSA 
infections that are acquired by 
persons who have not been  
recently (within the past year) 
hospitalized or had a medical 
procedure (such as dialysis, 
surgery, catheters) are known 
as CA-MRSA infections.  MRSA 
infections in the community are 
usually manifested as skin  
infections, such as pimples and 
boils, and occur in otherwise 
healthy people.  The majority of 
MRSA infections occur among 
patients in hospitals or other 
healthcare settings; however, it 
is becoming more common in 
the community setting.  CDC 
public information suggests that 
12% of clinical MRSA infections 
are community-associated, but 
this varies by geographic region 
and population (http://
www.cdc.gov/ncidod/dhqp/
ar_mrsa_ca_public.html). 
 Two other practice-based 
research networks in the  
country received this award; the 
State Network of Colorado  
Ambulatory Practices and  
Partners (SNOCAP) and North 
Carolina Network Consortium 
(NCNC).  The faculty at these 
three institutions will collaborate 
on this work. 
We  have evaluated the physician/pharmacist collaborative model in two studies funded by the National 
Heart, Lung and Blood Institute.  Both studies  
involved patients with uncontrolled hypertension.  
One study was just completed in seven of the Iowa  
Family Medicine residency training programs in the 
Iowa network, but the results of this study are still 
being analyzed.  Both studies involved clinics in the 
IRENE Network. 
We recently published the results of a cluster, ran-
domized trial of physician\pharmacist collaboration 
to improve blood pressure (BP) control in five  
university clinics in the Iowa City area.1  We enrolled 
179 patients seen by faculty physicians.  The  
intervention protocol specified a patient interview at 
baseline by the clinical pharmacist.  The pharmacist 
assessed the patient’s regimen, suggested a goal 
BP and provided recommendations to improve BP 
control.  BP control was defined as an office BP 
<130/80 mm Hg for patients with diabetes or chronic 
kidney disease and <140/90 mm Hg for all other  
patients.2   The protocol specified that pharmacists 
should recommend therapies consistent with JNC-7 
and educate the physician by providing background 
information if necessary.2   The primary focus of the 
pharmacists was to address suboptimal medication 
regimens.   
After adjustment for the covariates, the mean  
difference (control group minus the intervention 
group) in 9-month SBP was 8.7 (95% CI: 4.4, 12.9) 
mm Hg (Figure 1), while the adjusted mean  
difference in 9-month DBP was 5.4 (CI: 2.8, 8.0) mm 
Hg (data not shown).  The 24-hour BP effect size 
was nearly identical with a mean difference of 8.8  
(CI: 5.0, 12.6) mm Hg for SBP and 4.6 (CI: 2.4, 6.8) 
mm Hg for DBP.   
At 9 months, BP was controlled in 89% of patients in 
the intervention group and 53% in the control group 
(adjusted odds ratio 8.9; CI: 3.8, 20.7; p<0.001,  
Figure 2).   BP was controlled in 63% of  
non-diabetics in the control group and 91% in the 
intervention group (adjusted odds ratio of 10.2; CI: 
3.4, 29.9; p<0.001).  For patients with diabetes, BP 
was controlled in 24% of patients in the control 
group and 82% in the intervention group (adjusted 
odds ratio of 40.1; CI: 4.1, 394.7; p=0.002).   
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Blood Pressure Control by Visit
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Figure 2.  Blood pressure control based on clinic blood 
pressure based on <140/90 mm Hg for uncomplicated 
hypertension and <130/80 mm Hg for patients with 
diabetes or chronic kidney disease 
Systolic Blood Pressure by Visit
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Figure 1:  Clinic measured systolic BP 
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The baseline number of antihypertensive medica-
tions was not different between the intervention (1.5 
+ 1.0) and control groups (1.4 + 1.0).  By the end of 
the study, the mean number of antihypertensive 
medications was significantly higher (p=0.003) in 
the intervention group (2.4 + 0.9) when compared 
to the control group (1.9 + 1.0).   There was no  
difference in the side effect score at baseline (mean 
26.5 control group vs. 28.8 intervention group, 
p=0.397).  In spite of the increase in medi-
cations in both groups, side effect scores 
declined at 9 months to 18.3 in the control 
group (p=0.003 vs baseline) and 22.2 in 
the intervention group (p = 0.014 vs base-
line).  There was no difference in side ef-
fect scores between groups at 9-months 
(p=0.135).   
The clinical pharmacists made 267 recom-
mendations (2.6 per patient) to change BP 
medications, and physicians accepted 256 
(95.9%) in the intervention group.  Of all 
the drug-therapy (n=256) changes made by physi-
cians on the recommendations of the pharmacists, 
the majority were to increase the dose (34%), add 
another non-diuretic antihypertensive (30%) or add 
a thiazide diuretic (17%).  Other recommendations 
included to switch within class (5%), decrease a 
dose (4%), discontinue a drug (7%) or change dose 
frequency (3%).  Most of the recommendations 
(60%) occurred at or before the two-month visit.   
Physicians in the control group changed medica-
tions 100 times (1.28 per patient, p <0.001 com-
pared to the intervention group).   
This study focused hypertension management with 
the use of team-based care involving clinical phar-
macists located in the physician’s office.  One big 
question is whether similar results could be 
achieved (similar improvements in BP control) if 
private physicians and community pharmacists 
worked more collaboratively for specific patients 
with poorly controlled BP.  To that end, we are  
enrolling six IRENE clinics that will partner with a  
specific community pharmacy.  Later this fall, we 
will conduct teambuilding sessions with the physi-
cians and pharmacists.  Patients with poorly  
controlled BP will be identified and randomly  
assigned to a control or intervention group.   
Patients in the intervention group will have follow-up 
meetings with the pharmacists, who will then make  
recommendations to physicians to 
improve BP control.  The physicians 
will be free to accept, partially accept 
or reject the pharmacists’ recommen-
dations.  We will determine if such a 
model can significantly improve BP 
when compared to the control group.  
This study is designed to enroll about 
120 patients.  We will use this pilot 
data to develop a grant application to 
the National Heart, Lung and Blood  
Institute to conduct a larger study with 
longer follow-up.  We appreciate the willingness of 
physicians in the IRENE Network to participate in 
these studies and hope you will agree to the larger 
project in the future.  
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BACKGROUND: Fewer than half of Americans have been 
screened for colorectal cancer (CRC), a largely preventable 
disease.  
METHODS: All physician members (n = 1030) of the Iowa 
Academy of Family Physicians were mailed a 3-page investi-
gator-developed survey about their attitudes, barriers, and 
practices regarding CRC screening.  
RESULTS: The usable response rate was 29%. Forty-three 
percent practiced in rural settings. Ninety-five percent felt that 
they were well informed about American Cancer Society 
guidelines and 90% tried to follow the guidelines. Most doc-
tors (88%) disagreed with the statement that there was "no 
time to adequately discuss screening," but they would like 
more time to discuss screening. Only 40% felt their medical 
records were organized to easily determine screening status, 
40% encouraged office staff to participate in screening, and 
16% had a written policy regarding CRC screening. Physi-
cians estimated that they recommend screening to 78% of 
their patients and that 54% of their patients were actually up-
to-date. Discussion of CRC screening was strongly depend-
ent on visit type, with physicians estimating that CRC screen-
ing is discussed at 11% of acute visits, 42% of chronic visits, 
and 87% of health maintenance visits. Several office system 
factors were associated with a recommendation for screening 
in a multivariable linear regression model (R = 0.33).  
CONCLUSIONS: Although nearly all physicians felt that they 
were well informed about American Cancer Society guidelines 
and tried to follow guidelines for CRC screening, few had of-
fice systems to facilitate screening. Physicians would like 
more time to discuss screening. Office systems likely have 
the most potential to improve CRC screening among patients 
attending primary care practices. 
Permission is hereby granted on a non-exclusive, one-time basis to reprint 
the abstract from Med Care 2008;46(9 Suppl 1):S103-S108  
"Reprinted with permission of Lippincott Williams & Wilkins." 
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